Half-year report · HY
4564.TEDINET S100X054
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 42
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥432m | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥225m | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | −¥476m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | −¥531m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | −¥494m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥554m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥555m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥555m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.2bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.5bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥289m | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥426m | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥729m | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.0bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.7bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥834m | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.7bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥834m | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥528m | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥525m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥579m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥61m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥279,000 | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-1.89 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.12 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-2.18 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 81.4% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.9% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥185,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥185,000 |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥185m |
| Cancer Precision Medical Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥430m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥430m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥7m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥185,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥284m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥432m |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥432m |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥185,000 |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | −¥291m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥178m |
| Cancer Precision Medical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥222m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥222m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥94m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥259m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | −¥353m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 400
| Item | Context | Value | Unit |
|---|---|---|---|
| Address major shareholders | InterimInstant_No2MajorShareholdersMember | Original text (Japanese)大阪府大阪市住吉区 | |
| Name major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)特定有価証券信託受託者株式会社SMBC信託銀行 | |
| Address major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内1-3-2 | |
| Name major shareholders | InterimInstant_No4MajorShareholdersMember | Original text (Japanese)中鶴 修一 | |
| Address major shareholders | InterimInstant_No4MajorShareholdersMember | Original text (Japanese)埼玉県さいたま市中央区 | |
| Name major shareholders | InterimInstant_No5MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No5MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No6MajorShareholdersMember | Original text (Japanese)荒木 靖夫 | |
| Address major shareholders | InterimInstant_No6MajorShareholdersMember | Original text (Japanese)大阪府豊中市 | |
| Name major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)後藤 知近 | |
| Address major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)神奈川県川崎市宮前区 | |
| Name major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)仲榮眞 正雄 | |
| Address major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)沖縄県島尻郡南風原町 | |
| Name major shareholders | InterimInstant_No9MajorShareholdersMember | Original text (Japanese)古川 洋一 | |
| Address major shareholders | InterimInstant_No9MajorShareholdersMember | Original text (Japanese)東京都品川区 | |
| Name major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)日本証券金融株式会社 | |
| Address major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)東京都中央区日本橋茅場町1-2-10 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)オンコセラピー・サイエンス株式会社 | |
| Address of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)神奈川県川崎市川崎区東田町１番地２ | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | InterimDuration | Text · Plus | |
| Note on independent audit financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated balance sheet (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of comprehensive income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of cash flows (text) | InterimDuration | Text · Plus | |
| Notes regarding research and development expenses (text) | InterimDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes significant events after reporting period semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |